User:Jordynlazic/Apixaban

Dosing
There are different dosing regimens of Apixaban based on what is being treated and what the desired outcome is. The dosing for stroke prevention in patients with atrial fibrillation and one CHADS2 risk factor is 5 mg twice daily. Treatment of deep vein thrombosis and pulmonary embolism with Apixaban is 10 mg twice daily for 7 days, then 5 mg twice daily. Prophylaxis after recurrent deep vein thrombosis or pulmonary embolism and prevention of venous thromboembolism is 2.5 mg twice daily.

Apixaban can be taken irrespective of food.

Pharmacokinetics
Apixaban's half life is 12 hours. The renal excretion of Apixaban is 25% and is contraindicated in those with a creatinine clearance under 15 millilitres per minute. Apixaban has a bioavailability of greater than 60%. Peak plasma concentrations are reached in less than 4 hours for all direct oral anticoagulants.

Apixaban is a substrate of cytochrome P450 3A4, and the P-glycoprotein transporter. Therefore, inhibitors or inducers of CYP 3A4 enzymes or P-glycoproteins have the possibility of changing Apixaban exposure in the body.

Drug-Drug Interactions
The addition of Aspirin, to Apixaban therapy in patients with venous thromboembolism should be avoided as it nearly doubles bleeding rates.